Results 111 to 120 of about 184,127 (310)

Effectiveness and Safety of Reduced‐Dose Prasugrel in an East Asian Population: PRASFIT‐ACS Emulation Using National Health Insurance Claims Data

Clinical Pharmacology &Therapeutics, EarlyView.
Prasugrel is recommended for acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI). However, East Asians exhibit a stronger antiplatelet response, raising concerns about bleeding risks with standard dosing. This retrospective cohort study evaluated the real‐world effectiveness and safety of reduced‐dose prasugrel in
Li‐Wen Huang, Yee‐Jen Wu, Fang‐Ju Lin, Chien‐Chih Wu, Hsin‐Yi Huang, Chi‐Chuan Wang, Xiaojuan Li   +6 more
wiley   +1 more source

Re: Is there a difference in the effect between the angiotensin‐converting enzyme inhibitor and angiotensin‐receptor blocker on the COVID‐19? [PDF]

, 2020
Xiao Liu, Chuyan Long, Qinmei Xiong, Chen Chen, Jianyong Ma, Yuhao Su, Kui Hong   +6 more
openalex   +1 more source

Quantitative structure-activity relationship study of some angiotensin-converting enzyme inhibitor drugs in the treatment of hypertension based on Monte Carlo optimization method [PDF]

Majallah-i Dānishgāh-i ’Ulūm-i Pizishkī-i Īlām
Introduction:  Hypertension is a severe cardiovascular disease affecting human health, and its control and prevention are crucial for global health. Angiotensin-converting-enzyme inhibitors are primarily used in treating this condition.
Shahram Lotfi, Shahin Ahmadi, Ali Azimi
doaj  

Impact of Antihypertensive Treatment on Outcomes of Adjuvant Bevacizumab for Ovarian Cancer (IATRO), Results from a Nationwide Emulated Clinical Trial

Clinical Pharmacology &Therapeutics, EarlyView.
Antiangiogenic therapy with bevacizumab improves outcomes in ovarian cancer but induces hypertension, leading to major adverse cardiovascular events (MACE). While calcium channel blockers (CCBs) and angiotensin‐converting enzyme inhibitors (ACEi) are recommended for managing bevacizumab‐associated hypertension, their impacts on cancer progression and ...
Floriane Jochum, Élise Dumas, Joe‐Elie Salem, Stéphane Ederhy, Anne‐Sophie Hamy, Lise Lecointre, Enora Laas, Fabien Reyal, Fabrice Lecuru, Cherif Akladios, Paul Gougis   +10 more
wiley   +1 more source

The angiotensin-converting enzyme inhibitor, captopril, suppressed hepatic stellate cell activation via NF-kappaB or wnt3α/β-catenin pathway [PDF]

, 2021
Zhaodi Gu, Linjun Fang, Ma Pei-Jun
openalex   +1 more source

Socio‐economic inequalities and heart failure morbidity and mortality: A systematic review and data synthesis

ESC Heart Failure, Volume 12, Issue 2, Page 927-941, April 2025.
Abstract Socio‐economic status (SES) has been associated with incident and prevalent heart failure (HF), as well as its morbidity and mortality. However, the precise nature of the relationship between SES and HF remains unclear due to inconsistent data. This study aims to provide a comprehensive assessment and data synthesis of the relationship between
Abdul Shakoor, Willemijn A. van Maarschalkerwaart, Jeroen Schaap, Rudolf A. de Boer, Nicolas M. van Mieghem, Eric H. Boersma, Loek van Heerebeek, Jasper J. Brugts, Robert M.A. van der Boon   +8 more
wiley   +1 more source

Incident heart failure: comparing management and outcome in primary and hospital settings in Western Sweden 2008–2017

ESC Heart Failure, Volume 12, Issue 2, Page 832-838, April 2025.
Abstract Aim Heart failure (HF) is a highly prevalent condition managed in both primary care (PC) and hospital care (HC)‐based settings. HF patients managed in these two settings may differ in their demography, comorbidities and outcomes, so we aimed to compare the patient management in PC and HC in the Västra Götaland Region (VGR) in Sweden.
Xiaojing Chen, Aldina Pivodic, Maria Schaufelberger, Annika Rosengren, Michael Fu   +4 more
wiley   +1 more source

Transthyretin amyloid cardiomyopathy: Literature review and red‐flag symptom clusters for each cardiology specialty

ESC Heart Failure, Volume 12, Issue 2, Page 955-967, April 2025.
Abstract Wild‐type transthyretin amyloid cardiomyopathy (ATTRwt‐CM) is a progressive and infiltrative cardiac disorder that may cause fatal consequences if left untreated. The estimated survival time from diagnosis is approximately 3–6 years. Because of the non‐specificity of initial symptom manifestation and insufficient awareness among treating ...
Yasuhiro Izumiya, Toru Kubo, Jin Endo, Seiji Takashio, Masatoshi Minamisawa, Jun Hamada, Tomonori Ishii, Hajime Abe, Hiroaki Konishi, Kenichi Tsujita   +9 more
wiley   +1 more source

What is the association of acute renal failure, angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker in a young patient? [PDF]

, 2012
Selçuk Yüksel, Ali Koçyiğit, Ebru Uzun, Emre Tepeli, Vefa Özcan, Tülay Becerir   +5 more
openalex   +1 more source

Prognostic role of high‐sensitivity cardiac troponin T in patients with cardiac sarcoidosis: insights from ILLUMINATE‐CS

ESC Heart Failure, Volume 12, Issue 2, Page 869-878, April 2025.
Abstract Aims The prognostic role of high‐sensitivity cardiac troponin T (hs‐cTnT) as a biomarker in patients with cardiac sarcoidosis (CS) has yet to be fully determined, especially when compared with B‐type natriuretic peptide (BNP). Methods and Results In this post‐hoc analysis of the ILLUMINATE‐CS (ILLUstration of the Management and prognosIs of ...
Yuichi Baba, Toru Kubo, Takeru Nabeta, Yuya Matsue, Takeshi Kitai, Yoshihisa Naruse, Tatsunori Taniguchi, Hidekazu Tanaka, Takahiro Okumura, Kenji Yoshioka, Hiroaki Kitaoka   +10 more
wiley   +1 more source